Trastuzumab: A Review of its Use as Adjuvant Treatment in Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Early Breast Cancer

By Garnock-Jones Karly P.   Keating Gillian M.   Scott Lesley J.  

Drugs, Vol. 70, Iss. 2, 2010-01 ,pp. : 215-239

Adis International

Access to resources Recommend Favorite

Epidermal growth factor receptor gene copy number may predict lapatinib sensitivity in HER2-positive metastatic breast cancer

By Fabi Alessandra   Merola Roberta   Ferretti Gianluigi   Di Benedetto Anna   Antoniani Barbara   Ercolani Cristiana   Nisticò Cecilia   Papaldo Paola   Ciccarese Mariangela   Sperduti Isabella   Vici Patrizia   Marino Mirella   Gori Stefania   Botti Claudio   Malaguti Paola   Cognetti Francesco   Mottolese Marcella  

Expert Opinion on Pharmacotherapy, Vol. 14, Iss. 6, 2013-04 ,pp. : 699-706

Informa Healthcare

Access to resources Recommend Favorite

Sales of human epidermal growth factor receptor 2 (HER2)-targeting breast cancer therapies are set to grow by 3.3% per annum

By  

PharmacoEconomics and Outcomes News, Vol. 1, Iss. 592, 2009-01 ,pp. : 11-11

Adis International

Access to resources Recommend Favorite

Trastuzumab: A Review of its Use in the Management of HER2-Positive Metastatic and Early-Stage Breast Cancer

By Plosker Greg L.   Keam Susan J.  

Drugs, Vol. 66, Iss. 4, 2006-01 ,pp. : 449-475

Adis International

Access to resources Recommend Favorite

Pre-treatment Haemoglobin Concentration is a Prognostic Factor in Patients with Early-stage Breast Cancer

By Kandemir EG   Mayadagli A   Turken O   Yaylaci M   Ozturk A  

The Journal of International Medical Research, Vol. 33, Iss. 3, 2005-05 ,pp. : 319-328

Field House Publishing

Access to resources Recommend Favorite